Press Release

NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NeoGenomics Reports Revenue of $125 Million in the Second Quarter

NeoGenomics Announces Chief Executive Officer Appointment

NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients